お見積

サンプルお申込み

お問い合わせ

今すぐ購入

※ご注文方法：お問い合わせフォームまたはメールにてご連絡ください。
支払方法：「銀行振込」の場合， 注文の確認後、ご指定のメールアドレスに電子版の請求書をお送りいたしますので、電子版の請求書の記載事項に従って送金操作を行ってください。
※納期：原則として、受注後2～4営業日以内に発送いたします。 但し、日本語版が必要な場合は、受注後8～10営業日となります。 お客様のニーズに合わせて、事前にご注文のスケジュールをお立てください。

本報告書はRNAベースの治療薬とワクチン市場規模の世界市場の概要を紹介します。2019~2023年の歴史的な市場収益データ、2024年の予想、および2030年までのCAGRの予測を含む世界市場動向の分析。レポートはRNAベースの治療薬とワクチンの主要メーカーを詳細に分析し、地域別・国別の収益プロフィールを明らかにしています。 本レポートでは特に、主要地域/国別のセグメントとサブセグメントについて、将来の市場ポテンシャルの探索と予測に焦点を当てています。 複数の地域にわたる包括的なデータと市場価値分析により、読者は包括的かつ詳細な市場洞察を得ることができます。

世界のRNAベースの治療薬とワクチン市場の主な参加者である企業概要、収益、粗利益率、ポートフォリオ、地理的位置、重要な発展について、次のパラメータに基づいて説明します。レポートはRNAベースの治療薬とワクチンのメーカー、地域、種類と端末業界の角度から世界と主要地域の市場現状と将来性を研究した、このレポートでは、世界と主要地域のトップメーカーを分析し、タイプとアプリケーション/端末業界別にRNAベースの治療薬とワクチン市場を分類しています。本研究に含まれる主な企業は：Alnylam Pharmaceuticals、Arbutus Biopharma、Arrowhead Pharmaceuticals、BioNTech、CureVac、Dicerna Pharmaceuticals、Regulus Therapeutics、Marina Biotech、MiRagen Therapeutics、Moderna Therapeutics、Quark Pharmaceuticals、Roche、Sylentis

地域別市場区分、地域別分析は以下の通り：
    アメリカとカナダ
    中国
    アジア
    ヨーロッパ
    中東、アフリカ、ラテンアメリカ

タイプ別市場セグメント：
    RNA-Based Therapeutics
    RNA-Based Vaccines

用途別の市場セグメント：
    Oncology
    Immunology
    Ophthalmology
    Cardiovascular Diseases
    Infectious Diseases
    Genetic Diseases
    Others

本レポートの詳細内容
世界のRNAベースの治療薬とワクチン市場の現状と将来について、グローバルの主要地域を中心に包括的に分析しています。 当レポートでは、多角的な分析を通じて、市場プレイヤー、地域分布、RNAベースの治療薬とワクチンタイプ、最終用途アプリケーションなどの主要分野を掘り下げ、読者に包括的な市場洞察を提供しています。 レポートは主要企業のRNAベースの治療薬とワクチン収益、市場シェア、業界ランキング、2019年から2024年までのデータに焦点を当てています。世界のRNAベースの治療薬とワクチン市場における主要なステークホルダーの特定、最近の動向とセグメント収益に基づいて競争状況と市場ポジショニングの分析。また、当レポートでは、世界市場の主要プレイヤーを特定し、プロファイルを作成するとともに、RNAベースの治療薬とワクチン市場を綿密に分類・応用することで、読者が市場構造とダイナミクスをより正確に把握できるようにし、十分な情報に基づいた意思決定と戦略立案に強力なサポートを提供しています。

RNAベースの治療薬とワクチンのレポートは2019年から2030年までのタイプ別およびアプリケーション別、収益、成長率別のセグメントデータを分析します。収益、予測成長傾向、アプリケーション、およびエンドユーザー業界の市場規模を評価および予測します。

章の概要
第1章：RNAベースの治療薬とワクチンのレポートの報告範囲、各セグメントの市場規模、将来の開発可能性などを含む、さまざまな市場セグメント（製品タイプ、用途など）のエグゼクティブサマリーを紹介します。市場の現状と、短期から中期、および長期的な進化の可能性をハイレベルに見ることができます。（2019～2030）
第2章：RNAベースの治療薬とワクチンの世界及び地域レベルでの売上高。各地域とその主要国の市場規模と発展の可能性を定量的に分析し、世界各国の市場発展、今後の発展展望、市場空間、生産能力などを紹介する。また、市場ダイナミクス、市場の最新動向、市場の推進要因と制限要因、業界企業が直面する課題とリスク、業界の関連政策の分析などを紹介しています。（2019～2030）
第3章RNAベースの治療薬とワクチン企業の競争状況、収益、市場シェアと業界ランキング、最新の開発計画、合併・買収情報などの詳細分析。（2019～2030）
第4章：各市場セグメントの収益と開発の可能性をカバーし、種類別のさまざまな市場セグメントの分析を提供し、読者がさまざまな市場セグメントでブルーオーシャン市場を見つけるのに役立ちます。（2019～2024）
第5章：RNAベースの治療薬とワクチンの各市場セグメントの収益と開発の可能性をカバーするアプリケーション別のさまざまな市場セグメントの分析を提供し、読者がさまざまな下流市場でブルーオーシャン市場を見つけるのに役立ちます。（2019～2030）
第6章：北米（米国、カナダ）のタイプ別、アプリケーション別、国別、各セグメントの収益。（2019～2030）
第7章：ヨーロッパのタイプ別、アプリケーション別、国別、各セグメントの収益。（2019～2030）
第8章：中国の種類別、および用途別、各セグメントの収益。（2019～2030）
第9章アジア（中国を除く）の種類別、用途別、地域別、セグメントごとの収益。（2019～2030）
第10章：中東、アフリカ、ラテンアメリカの種類別、アプリケーション別、国別、各セグメントの収益。（2019～2030）
第11章：RNAベースの治療薬とワクチンの主要企業の概要を提供し、製品の説明と仕様、RNAベースの治療薬とワクチンの収益、粗利益率、最近の展開など、市場の主要企業の基本状況を詳細に紹介します。（2019～2024）
第12章：アナリストの見解/結論

RNA-based biopharmaceuticals, which includes therapeutics and vaccines, is a relatively new class of treatment and prophylactic for a number of chronic and rare diseases, including cancer, diabetes, tuberculosis and certaincardiovascular conditions.

Market Analysis and Insights: Global RNA-Based Therapeutics and Vaccines Market
The global RNA-Based Therapeutics and Vaccines market is projected to grow from US$ 42 million in 2024 to US$ 634.8 million by 2030, at a Compound Annual Growth Rate (CAGR) of 57.3% during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers:
This report presents an overview of global market for RNA-Based Therapeutics and Vaccines market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030. 
This report researches the key producers of RNA-Based Therapeutics and Vaccines, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for RNA-Based Therapeutics and Vaccines, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the RNA-Based Therapeutics and Vaccines revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global RNA-Based Therapeutics and Vaccines market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for RNA-Based Therapeutics and Vaccines revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Alnylam Pharmaceuticals, Arbutus Biopharma, Arrowhead Pharmaceuticals, BioNTech, CureVac, Dicerna Pharmaceuticals, Regulus Therapeutics, Marina Biotech and MiRagen Therapeutics, etc.

Market Segmentation
By Company
    Alnylam Pharmaceuticals
    Arbutus Biopharma
    Arrowhead Pharmaceuticals
    BioNTech
    CureVac
    Dicerna Pharmaceuticals
    Regulus Therapeutics
    Marina Biotech
    MiRagen Therapeutics
    Moderna Therapeutics
    Quark Pharmaceuticals
    Roche
    Sylentis

Segment by Type
    RNA-Based Therapeutics
    RNA-Based Vaccines

Segment by Application
    Oncology
    Immunology
    Ophthalmology
    Cardiovascular Diseases
    Infectious Diseases
    Genetic Diseases
    Others

By Region
    North America
        United States
        Canada
    Europe
        Germany
        France
        UK
        Italy
        Russia
        Nordic Countries
        Rest of Europe
    China
    Asia (excluding China)
        Japan
        South Korea
        China Taiwan
       Southeast Asia
        India
    Latin America, Middle East & Africa
        Brazil
        Mexico
        Turkey
        Israel
        GCC Countries

Chapter Outline
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of RNA-Based Therapeutics and Vaccines in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of RNA-Based Therapeutics and Vaccines companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, RNA-Based Therapeutics and Vaccines revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions

List of Tables
    Table 1. Global RNA-Based Therapeutics and Vaccines Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
    Table 2. Key Players of RNA-Based Therapeutics
    Table 3. Key Players of RNA-Based Vaccines
    Table 4. Global RNA-Based Therapeutics and Vaccines Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
    Table 5. Global RNA-Based Therapeutics and Vaccines Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 6. Global RNA-Based Therapeutics and Vaccines Market Size by Region (2019-2024) & (US$ Million)
    Table 7. Global RNA-Based Therapeutics and Vaccines Market Share by Region (2019-2024)
    Table 8. Global RNA-Based Therapeutics and Vaccines Forecasted Market Size by Region (2025-2030) & (US$ Million)
    Table 9. Global RNA-Based Therapeutics and Vaccines Market Share by Region (2025-2030)
    Table 10. RNA-Based Therapeutics and Vaccines Market Trends
    Table 11. RNA-Based Therapeutics and Vaccines Market Drivers
    Table 12. RNA-Based Therapeutics and Vaccines Market Challenges
    Table 13. RNA-Based Therapeutics and Vaccines Market Restraints
    Table 14. Global RNA-Based Therapeutics and Vaccines Revenue by Players (2019-2024) & (US$ Million)
    Table 15. Global RNA-Based Therapeutics and Vaccines Revenue Share by Players (2019-2024)
    Table 16. Global Top RNA-Based Therapeutics and Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in RNA-Based Therapeutics and Vaccines as of 2023)
    Table 17. Global RNA-Based Therapeutics and Vaccines Industry Ranking 2022 VS 2023 VS 2024
    Table 18. Global 5 Largest Players Market Share by RNA-Based Therapeutics and Vaccines Revenue (CR5 and HHI) & (2019-2024)
    Table 19. Global Key Players of RNA-Based Therapeutics and Vaccines, Headquarters and Area Served
    Table 20. Global Key Players of RNA-Based Therapeutics and Vaccines, Product and Application
    Table 21. Global Key Players of RNA-Based Therapeutics and Vaccines, Product and Application
    Table 22. Mergers & Acquisitions, Expansion Plans
    Table 23. Global RNA-Based Therapeutics and Vaccines Market Size by Type (2019-2024) & (US$ Million)
    Table 24. Global RNA-Based Therapeutics and Vaccines Revenue Market Share by Type (2019-2024)
    Table 25. Global RNA-Based Therapeutics and Vaccines Forecasted Market Size by Type (2025-2030) & (US$ Million)
    Table 26. Global RNA-Based Therapeutics and Vaccines Revenue Market Share by Type (2025-2030)
    Table 27. Global RNA-Based Therapeutics and Vaccines Market Size by Application (2019-2024) & (US$ Million)
    Table 28. Global RNA-Based Therapeutics and Vaccines Revenue Share by Application (2019-2024)
    Table 29. Global RNA-Based Therapeutics and Vaccines Forecasted Market Size by Application (2025-2030) & (US$ Million)
    Table 30. Global RNA-Based Therapeutics and Vaccines Revenue Share by Application (2025-2030)
    Table 31. North America RNA-Based Therapeutics and Vaccines Market Size by Type (2019-2024) & (US$ Million)
    Table 32. North America RNA-Based Therapeutics and Vaccines Market Size by Type (2025-2030) & (US$ Million)
    Table 33. North America RNA-Based Therapeutics and Vaccines Market Size by Application (2019-2024) & (US$ Million)
    Table 34. North America RNA-Based Therapeutics and Vaccines Market Size by Application (2025-2030) & (US$ Million)
    Table 35. North America RNA-Based Therapeutics and Vaccines Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 36. North America RNA-Based Therapeutics and Vaccines Market Size by Country (2019-2024) & (US$ Million)
    Table 37. North America RNA-Based Therapeutics and Vaccines Market Size by Country (2025-2030) & (US$ Million)
    Table 38. Europe RNA-Based Therapeutics and Vaccines Market Size by Type (2019-2024) & (US$ Million)
    Table 39. Europe RNA-Based Therapeutics and Vaccines Market Size by Type (2025-2030) & (US$ Million)
    Table 40. Europe RNA-Based Therapeutics and Vaccines Market Size by Application (2019-2024) & (US$ Million)
    Table 41. Europe RNA-Based Therapeutics and Vaccines Market Size by Application (2025-2030) & (US$ Million)
    Table 42. Europe RNA-Based Therapeutics and Vaccines Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 43. Europe RNA-Based Therapeutics and Vaccines Market Size by Country (2019-2024) & (US$ Million)
    Table 44. Europe RNA-Based Therapeutics and Vaccines Market Size by Country (2025-2030) & (US$ Million)
    Table 45. China RNA-Based Therapeutics and Vaccines Market Size by Type (2019-2024) & (US$ Million)
    Table 46. China RNA-Based Therapeutics and Vaccines Market Size by Type (2025-2030) & (US$ Million)
    Table 47. China RNA-Based Therapeutics and Vaccines Market Size by Application (2019-2024) & (US$ Million)
    Table 48. China RNA-Based Therapeutics and Vaccines Market Size by Application (2025-2030) & (US$ Million)
    Table 49. Asia RNA-Based Therapeutics and Vaccines Market Size by Type (2019-2024) & (US$ Million)
    Table 50. Asia RNA-Based Therapeutics and Vaccines Market Size by Type (2025-2030) & (US$ Million)
    Table 51. Asia RNA-Based Therapeutics and Vaccines Market Size by Application (2019-2024) & (US$ Million)
    Table 52. Asia RNA-Based Therapeutics and Vaccines Market Size by Application (2025-2030) & (US$ Million)
    Table 53. Asia RNA-Based Therapeutics and Vaccines Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 54. Asia RNA-Based Therapeutics and Vaccines Market Size by Region (2019-2024) & (US$ Million)
    Table 55. Asia RNA-Based Therapeutics and Vaccines Market Size by Region (2025-2030) & (US$ Million)
    Table 56. Middle East, Africa, and Latin America RNA-Based Therapeutics and Vaccines Market Size by Type (2019-2024) & (US$ Million)
    Table 57. Middle East, Africa, and Latin America RNA-Based Therapeutics and Vaccines Market Size by Type (2025-2030) & (US$ Million)
    Table 58. Middle East, Africa, and Latin America RNA-Based Therapeutics and Vaccines Market Size by Application (2019-2024) & (US$ Million)
    Table 59. Middle East, Africa, and Latin America RNA-Based Therapeutics and Vaccines Market Size by Application (2025-2030) & (US$ Million)
    Table 60. Middle East, Africa, and Latin America RNA-Based Therapeutics and Vaccines Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 61. Middle East, Africa, and Latin America RNA-Based Therapeutics and Vaccines Market Size by Country (2019-2024) & (US$ Million)
    Table 62. Middle East, Africa, and Latin America RNA-Based Therapeutics and Vaccines Market Size by Country (2025-2030) & (US$ Million)
    Table 63. Alnylam Pharmaceuticals Company Details
    Table 64. Alnylam Pharmaceuticals Business Overview
    Table 65. Alnylam Pharmaceuticals RNA-Based Therapeutics and Vaccines Product
    Table 66. Alnylam Pharmaceuticals Revenue in RNA-Based Therapeutics and Vaccines Business (2019-2024) & (US$ Million)
    Table 67. Alnylam Pharmaceuticals Recent Developments
    Table 68. Arbutus Biopharma Company Details
    Table 69. Arbutus Biopharma Business Overview
    Table 70. Arbutus Biopharma RNA-Based Therapeutics and Vaccines Product
    Table 71. Arbutus Biopharma Revenue in RNA-Based Therapeutics and Vaccines Business (2019-2024) & (US$ Million)
    Table 72. Arbutus Biopharma Recent Developments
    Table 73. Arrowhead Pharmaceuticals Company Details
    Table 74. Arrowhead Pharmaceuticals Business Overview
    Table 75. Arrowhead Pharmaceuticals RNA-Based Therapeutics and Vaccines Product
    Table 76. Arrowhead Pharmaceuticals Revenue in RNA-Based Therapeutics and Vaccines Business (2019-2024) & (US$ Million)
    Table 77. Arrowhead Pharmaceuticals Recent Developments
    Table 78. BioNTech Company Details
    Table 79. BioNTech Business Overview
    Table 80. BioNTech RNA-Based Therapeutics and Vaccines Product
    Table 81. BioNTech Revenue in RNA-Based Therapeutics and Vaccines Business (2019-2024) & (US$ Million)
    Table 82. BioNTech Recent Developments
    Table 83. CureVac Company Details
    Table 84. CureVac Business Overview
    Table 85. CureVac RNA-Based Therapeutics and Vaccines Product
    Table 86. CureVac Revenue in RNA-Based Therapeutics and Vaccines Business (2019-2024) & (US$ Million)
    Table 87. CureVac Recent Developments
    Table 88. Dicerna Pharmaceuticals Company Details
    Table 89. Dicerna Pharmaceuticals Business Overview
    Table 90. Dicerna Pharmaceuticals RNA-Based Therapeutics and Vaccines Product
    Table 91. Dicerna Pharmaceuticals Revenue in RNA-Based Therapeutics and Vaccines Business (2019-2024) & (US$ Million)
    Table 92. Dicerna Pharmaceuticals Recent Developments
    Table 93. Regulus Therapeutics Company Details
    Table 94. Regulus Therapeutics Business Overview
    Table 95. Regulus Therapeutics RNA-Based Therapeutics and Vaccines Product
    Table 96. Regulus Therapeutics Revenue in RNA-Based Therapeutics and Vaccines Business (2019-2024) & (US$ Million)
    Table 97. Regulus Therapeutics Recent Developments
    Table 98. Marina Biotech Company Details
    Table 99. Marina Biotech Business Overview
    Table 100. Marina Biotech RNA-Based Therapeutics and Vaccines Product
    Table 101. Marina Biotech Revenue in RNA-Based Therapeutics and Vaccines Business (2019-2024) & (US$ Million)
    Table 102. Marina Biotech Recent Developments
    Table 103. MiRagen Therapeutics Company Details
    Table 104. MiRagen Therapeutics Business Overview
    Table 105. MiRagen Therapeutics RNA-Based Therapeutics and Vaccines Product
    Table 106. MiRagen Therapeutics Revenue in RNA-Based Therapeutics and Vaccines Business (2019-2024) & (US$ Million)
    Table 107. MiRagen Therapeutics Recent Developments
    Table 108. Moderna Therapeutics Company Details
    Table 109. Moderna Therapeutics Business Overview
    Table 110. Moderna Therapeutics RNA-Based Therapeutics and Vaccines Product
    Table 111. Moderna Therapeutics Revenue in RNA-Based Therapeutics and Vaccines Business (2019-2024) & (US$ Million)
    Table 112. Moderna Therapeutics Recent Developments
    Table 113. Quark Pharmaceuticals Company Details
    Table 114. Quark Pharmaceuticals Business Overview
    Table 115. Quark Pharmaceuticals RNA-Based Therapeutics and Vaccines Product
    Table 116. Quark Pharmaceuticals Revenue in RNA-Based Therapeutics and Vaccines Business (2019-2024) & (US$ Million)
    Table 117. Quark Pharmaceuticals Recent Developments
    Table 118. Roche Company Details
    Table 119. Roche Business Overview
    Table 120. Roche RNA-Based Therapeutics and Vaccines Product
    Table 121. Roche Revenue in RNA-Based Therapeutics and Vaccines Business (2019-2024) & (US$ Million)
    Table 122. Roche Recent Developments
    Table 123. Sylentis Company Details
    Table 124. Sylentis Business Overview
    Table 125. Sylentis RNA-Based Therapeutics and Vaccines Product
    Table 126. Sylentis Revenue in RNA-Based Therapeutics and Vaccines Business (2019-2024) & (US$ Million)
    Table 127. Sylentis Recent Developments
    Table 128. Research Programs/Design for This Report
    Table 129. Key Data Information from Secondary Sources
    Table 130. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global RNA-Based Therapeutics and Vaccines Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 2. Global RNA-Based Therapeutics and Vaccines Market Share by Type: 2023 VS 2030
    Figure 3. RNA-Based Therapeutics Features
    Figure 4. RNA-Based Vaccines Features
    Figure 5. Global RNA-Based Therapeutics and Vaccines Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 6. Global RNA-Based Therapeutics and Vaccines Market Share by Application: 2023 VS 2030
    Figure 7. Oncology Case Studies
    Figure 8. Immunology Case Studies
    Figure 9. Ophthalmology Case Studies
    Figure 10. Cardiovascular Diseases Case Studies
    Figure 11. Infectious Diseases Case Studies
    Figure 12. Genetic Diseases Case Studies
    Figure 13. Others Case Studies
    Figure 14. RNA-Based Therapeutics and Vaccines Report Years Considered
    Figure 15. Global RNA-Based Therapeutics and Vaccines Market Size (US$ Million), Year-over-Year: 2019-2030
    Figure 16. Global RNA-Based Therapeutics and Vaccines Market Size, (US$ Million), 2019 VS 2023 VS 2030
    Figure 17. Global RNA-Based Therapeutics and Vaccines Market Share by Region: 2023 VS 2030
    Figure 18. Global RNA-Based Therapeutics and Vaccines Market Share by Players in 2023
    Figure 19. Global Top RNA-Based Therapeutics and Vaccines Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in RNA-Based Therapeutics and Vaccines as of 2023)
    Figure 20. The Top 10 and 5 Players Market Share by RNA-Based Therapeutics and Vaccines Revenue in 2023
    Figure 21. North America RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 22. North America RNA-Based Therapeutics and Vaccines Market Share by Type (2019-2030)
    Figure 23. North America RNA-Based Therapeutics and Vaccines Market Share by Application (2019-2030)
    Figure 24. North America RNA-Based Therapeutics and Vaccines Market Share by Country (2019-2030)
    Figure 25. United States RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 26. Canada RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 27. Europe RNA-Based Therapeutics and Vaccines Market Size YoY (2019-2030) & (US$ Million)
    Figure 28. Europe RNA-Based Therapeutics and Vaccines Market Share by Type (2019-2030)
    Figure 29. Europe RNA-Based Therapeutics and Vaccines Market Share by Application (2019-2030)
    Figure 30. Europe RNA-Based Therapeutics and Vaccines Market Share by Country (2019-2030)
    Figure 31. Germany RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 32. France RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 33. U.K. RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 34. Italy RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 35. Russia RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 36. Nordic Countries RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 37. China RNA-Based Therapeutics and Vaccines Market Size YoY (2019-2030) & (US$ Million)
    Figure 38. China RNA-Based Therapeutics and Vaccines Market Share by Type (2019-2030)
    Figure 39. China RNA-Based Therapeutics and Vaccines Market Share by Application (2019-2030)
    Figure 40. Asia RNA-Based Therapeutics and Vaccines Market Size YoY (2019-2030) & (US$ Million)
    Figure 41. Asia RNA-Based Therapeutics and Vaccines Market Share by Type (2019-2030)
    Figure 42. Asia RNA-Based Therapeutics and Vaccines Market Share by Application (2019-2030)
    Figure 43. Asia RNA-Based Therapeutics and Vaccines Market Share by Region (2019-2030)
    Figure 44. Japan RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 45. South Korea RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 46. China Taiwan RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 47. Southeast Asia RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 48. India RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 49. Australia RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 50. Middle East, Africa, and Latin America RNA-Based Therapeutics and Vaccines Market Size YoY (2019-2030) & (US$ Million)
    Figure 51. Middle East, Africa, and Latin America RNA-Based Therapeutics and Vaccines Market Share by Type (2019-2030)
    Figure 52. Middle East, Africa, and Latin America RNA-Based Therapeutics and Vaccines Market Share by Application (2019-2030)
    Figure 53. Middle East, Africa, and Latin America RNA-Based Therapeutics and Vaccines Market Share by Country (2019-2030)
    Figure 54. Brazil RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 55. Mexico RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 56. Turkey RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 57. Saudi Arabia RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 58. Israel RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 59. GCC Countries RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 60. Alnylam Pharmaceuticals Revenue Growth Rate in RNA-Based Therapeutics and Vaccines Business (2019-2024)
    Figure 61. Arbutus Biopharma Revenue Growth Rate in RNA-Based Therapeutics and Vaccines Business (2019-2024)
    Figure 62. Arrowhead Pharmaceuticals Revenue Growth Rate in RNA-Based Therapeutics and Vaccines Business (2019-2024)
    Figure 63. BioNTech Revenue Growth Rate in RNA-Based Therapeutics and Vaccines Business (2019-2024)
    Figure 64. CureVac Revenue Growth Rate in RNA-Based Therapeutics and Vaccines Business (2019-2024)
    Figure 65. Dicerna Pharmaceuticals Revenue Growth Rate in RNA-Based Therapeutics and Vaccines Business (2019-2024)
    Figure 66. Regulus Therapeutics Revenue Growth Rate in RNA-Based Therapeutics and Vaccines Business (2019-2024)
    Figure 67. Marina Biotech Revenue Growth Rate in RNA-Based Therapeutics and Vaccines Business (2019-2024)
    Figure 68. MiRagen Therapeutics Revenue Growth Rate in RNA-Based Therapeutics and Vaccines Business (2019-2024)
    Figure 69. Moderna Therapeutics Revenue Growth Rate in RNA-Based Therapeutics and Vaccines Business (2019-2024)
    Figure 70. Quark Pharmaceuticals Revenue Growth Rate in RNA-Based Therapeutics and Vaccines Business (2019-2024)
    Figure 71. Roche Revenue Growth Rate in RNA-Based Therapeutics and Vaccines Business (2019-2024)
    Figure 72. Sylentis Revenue Growth Rate in RNA-Based Therapeutics and Vaccines Business (2019-2024)
    Figure 73. Bottom-up and Top-down Approaches for This Report
    Figure 74. Data Triangulation
    Figure 75. Key Executives Interviewed